Efficacy of enhanced extracorporeal counterpulsation combined with atorvastatin in the treatment of cognitive impairment after stroke

Table 4 Comparison of serum β2-microglobulin, glial fibrillary acidic protein, and visinin-like protein 1 concentrations between the two groups (mean ± SD)

Group	Β2-MG (mg/L)		VILIP-1 (ng/L)		GFAP (mg/L)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Study group (n = 30)	2.64 ± 0.65	1.49 ± 0.48a	520.59 ± 55.39	409.67 ± 40.77a	9.17 ± 1.32	6.04 ± 1.70a
Control group (n = 30)	2.79 ± 0.42	1.93 ± 0.28a	531.47 ± 54.03	435.83 ± 37.09a	9.87 ± 1.56	7.44 ± 1.06a
P value	0.294	< 0.001	0.444	0.012	0.064	< 0.001
t value	1.061	4.339	0.771	2.599	1.888	3.817

^aP < 0.05 compared to the same group before treatment.

β2-MG: β2-microglobulin; GFAP: Glial fibrillary acidic protein; VILIP-1: Visinin-like protein 1.